Your GLP-1 Monitoring Timeline
A structured 4-node testing program that tracks your molecular response from your initial baseline through long-term maintenance. Each node is timed to capture critical phases of your GLP-1 therapy.
Four Nodes.
Every Critical Phase.
Each testing node is strategically timed to capture a distinct phase of your GLP-1 therapy journey.
Baseline Profile
What's Tested
Whole-blood transcriptomic profiling across 3 Health Domains (Activation, Antiviral Response, and Resolution) with cellular deconvolution.
What You Learn
Your personal starting immune benchmark and circulating leukocyte census. Establishes the baseline reference against which all longitudinal changes are measured — whether you are preparing for your first dose or already weeks into therapy.
Early Response & Kinetics
What's Tested
Second whole-blood RNA profiling capturing early gene expression shifts across all 3 Health Domains.
What You Learn
Early systemic calming kinetics. Clinical trials (such as the SELECT trial) demonstrate that GLP-1 medications begin reducing systemic inflammatory signaling weeks before substantial weight loss occurs. Node 2 reveals whether innate immune programs are beginning to cool.
Provides an objective molecular window into biological calming early in dose titration, independent of bathroom scale fluctuations.
Metabolic Adaptation & Resolution
What's Tested
Comprehensive 3-domain transcriptomic profiling with longitudinal change analysis against Baseline and Month 1.
What You Learn
Consolidated inflammatory adaptation. By 12 weeks, as visceral adipose tissue reduces, Node 3 evaluates whether active resolution pathways have engaged to support tissue remodeling or whether residual activation pathways remain elevated.
Particularly valuable during weight-loss plateaus, giving clinicians objective biological context on whether metabolic inflammation continues to resolve even when scale weight holds steady.
Maintenance & Off-Ramp Monitoring
What's Tested
Annual whole-blood transcriptomic surveillance and structured off-ramp monitoring during medication tapering or post-discontinuation.
What You Learn
Surveillance for cellular inflammatory recurrence. Real-world cohort registries show that 65% of patients discontinue GLP-1 medications within year 1 (Truveta, n=125,474), with 3-year persistence dropping to ~8% (Prime Therapeutics). Because adipose tissue retains an epigenetic memory of obesity (Hinte et al., Nature 2024) and trial extensions (STEP 1, SURMOUNT-4) document rapid rebound upon cessation, Node 4 monitors whether systemic calming remains stable or if inflammatory activation signals resurface during maintenance, dose tapering, or off-ramping.
Equips you and your clinician with objective immune data to evaluate biological stability when adjusting dosage, transitioning to maintenance, or stopping medication.
Explore the Off-Ramp Testing Protocol →Testing Overview
| Node | Timing | What's Tested | What You Learn |
|---|---|---|---|
| 1 — Baseline | Day 0 (Initial Starting Point) | Whole-blood transcriptomics (3 domains + deconvolution) | Personal starting baseline & reference expression levels (before starting or upon entry) |
| 2 — 1 Month | Week 4 | Follow-up RNA profiling | Early systemic calming kinetics & weight-independent cooling |
| 3 — 3 Months | Week 12 | 3-Domain RNA profiling & longitudinal change | Consolidated metabolic adaptation & active resolution signaling |
| 4 — Maintenance & Off-Ramp | Month 12+ & Discontinuation | Annual transcriptomics & off-ramp tracking | Surveillance for cellular inflammatory recurrence & biological stability |
All nodes include at-home mobile phlebotomy and secure dashboard delivery. Results delivered within ~1 month.
Structured Surveillance During
Tapering & Discontinuation
Discontinuing or tapering a GLP-1 receptor agonist is the defining crossroads of therapy. Real-world registry data reveals that 65% of patients discontinue within 12 months (Truveta), and trial extensions (STEP 1, SURMOUNT-4) document rapid weight and cardiometabolic rebound. Because adipose tissue retains durable epigenetic memory of obesity (Hinte et al., Nature 2024), structured transcriptomic testing provides objective data to evaluate cellular stability alongside your physician.
Pre-Taper Molecular Benchmark
2–4 Weeks Prior to Dose Reduction or Spacing
Before adjusting your medication dose, draw a maintenance sample to establish your personal molecular reference point under steady-state therapy.
Post-Taper / Off-Ramp Surveillance
3 to 6 Months Post-Reduction or Cessation
Follow up 3 to 6 months after reducing dosage or completing your off-ramp to evaluate whether anti-inflammatory and metabolic gains are self-sustaining.
What the 3 Health Domains Reveal During the Off-Ramp
Innate Calming Stability
Tracks whether TLR danger sensing, IL-1 signaling, and neutrophil deployment remain low. A stable score confirms metabolic inflammatory suppression holds; a rising score flags covert reactivation before scale weight changes.
Resolution Autonomy
Evaluates whether active biochemical programs that end inflammation, clear cellular debris, and restore tissue homeostasis operate independently without pharmacological incretin support.
Leukocyte Population Balance
Quantifies leukocyte population fractions (monocytes, neutrophils, lymphocytes), confirming that immune cellular composition maintains a lean, balanced phenotype rather than shifting toward an obesity-associated cellular census.
Clinical Collaboration Note: The Inflammation Compass™ is an objective wellness monitoring test. It does not diagnose disease or prescribe medication regimens. All dosage adjustments, tapering schedules, and discontinuation plans should be developed in close partnership with your licensed healthcare provider.
Leading vs.
Lagging Indicators
Traditional Lab Markers
Blood chemistry snapshots that show what has already accumulated. Standard labs like hs-CRP (a single liver-produced protein) and HbA1c reflect accumulated systemic changes over weeks to months. They are valuable reactive checks, but they cannot tell you which immune programs are active or whether resolution is underway.
Transcriptomic Monitoring
Whole-blood RNA profiling reveals what circulating immune cells are actively transcribing right now. By mapping gene expression across Activation, Antiviral Response, and Resolution — and separating cell counts from activation states — transcriptomics captures the dynamic inflammatory arc during titration, maintenance, and tapering.
The Biomeme Labs testing schedule is designed around the biology — testing at the moments when molecular changes are most detectable and most actionable.
Start Your Monitoring
Program
Starting at $600 for your baseline package — with optional continuous monitoring at $250 per node at your chosen cadence.